This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (August 2024) |
JTK-109 is an antiviral drug which acts as a NS5B RNA-dependent RNA polymerase inhibitor. It was initially developed for the treatment of Hepatitis C, but also shows activity against caliciviruses such as norovirus.[1][2][3][4]
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C37H33ClFN3O4 |
Molar mass | 638.14 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ Hirashima S, Suzuki T, Ishida T, Noji S, Yata S, Ando I, et al. (July 2006). "Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109". Journal of Medicinal Chemistry. 49 (15): 4721–4736. doi:10.1021/jm060269e. PMID 16854079.
- ^ Hirashima S, Oka T, Ikegashira K, Noji S, Yamanaka H, Hara Y, et al. (June 2007). "Further studies on hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors toward improved replicon cell activities: benzimidazole and structurally related compounds bearing the 2-morpholinophenyl moiety". Bioorganic & Medicinal Chemistry Letters. 17 (11): 3181–3186. doi:10.1016/j.bmcl.2007.03.027. PMID 17383878.
- ^ Netzler NE, Enosi Tuipulotu D, Eltahla AA, Lun JH, Ferla S, Brancale A, et al. (October 2017). "Broad-spectrum non-nucleoside inhibitors for caliciviruses". Antiviral Research. 146: 65–75. doi:10.1016/j.antiviral.2017.07.014. PMID 28757394.
- ^ Netzler NE, Enosi Tuipulotu D, White PA (May 2019). "Norovirus antivirals: Where are we now?". Medicinal Research Reviews. 39 (3): 860–886. doi:10.1002/med.21545. PMC 7168425. PMID 30584800.